Abstract
Background: P-glycoprotein (P-gp) is linked to Alzheimer's disease (AD), as P-gp contributes to clearance of amyloid-β (Aβ) from the CNS. Thus, other P-gp substrates (Pgp-S) could affect Aβ clearance, either negatively through competitive inhibition or positively via cooperative transport, impacting risk for AD. Objective: We probed impacts of Pgp-S on AD risk by querying AD rates among individuals prescribed medications that are considered Pgp-S. Methods: A retrospective cohort study was performed using the PharMetrics Plus database (IQVIA), encompassing 70,340 users of prescription drugs identified as Pgp-S and 352,382 Pgp-S non-users. Users and non-users were matched by age, sex, and geographical region. Cox regression models afforded adjustments for covariates and comorbidities. Results: Pgp-S use was generally associated with a significant reduction in the hazard ratio of AD in both crude (HR = 0.89, 95% CI = 0.79–0.99) and matched (HR = 0.87; 95% CI = 0.78–0.98) analyses. AD risk was higher among subsets diagnosed with comorbidities: depression (HR = 4.44; 95% CI, 3.99–4.94), stroke (HR = 1.98, 95% CI = 1.63–2.41), and hypertension (HR = 1.24, 95% CI = 1.13–1.36). In an analysis of individual drugs, digoxin (OR = 0.52, 95% CI, 0.34–0.77), atorvastatin (OR = 0.80, 95% CI, 0.73–0.87), omeprazole (OR = 0.83, 95% CI, 0.73–0.94), and prednisone (OR = 0.64, 95% CI, 0.46–0.86) were associated with significantly decreased odds of incident AD; rivaroxaban (OR = 1.29, 95% CI = 0.97–1.68) and mirabegron (OR = 1.45, 95% CI = 0.86–2.28) trended toward increased risk. Conclusions: The findings suggest an association between Pgp-S use and AD, but limitations of the study design impel additional work to confirm the direction of impact for individual drugs.

This publication has 52 references indexed in Scilit: